Novel therapies under development for nephrotic syndrome

Sharing is caring!

Novel therapies under development for nephrotic syndrome

Are there novel therapies for nephrotic syndrome that are under development?

Dietary interventions, such as a gluten-free diet, may be useful in a subset of children with MCNS. Rituximab, a monoclonal antibody to CD20 on B-cells, is being tested in the full array of causes of nephrotic syndrome.

Abatacept, a monoclonal antibody to B7.1, has been shown to be effective in inducing remission of proteinuria in the open-label treatment of patients with FSGS and is being evaluated in an ongoing randomized clinical trial.

Strategies to prevent kidney fibrosis using thiazolidinediones (rosiglitazone) and monoclonal anti-tumor necrosis factor antibodies (adalimumab) are under evaluation to protect the kidney in resistant forms of nephrotic syndrome.

The identification of a subgroup of patients with a specific disease mechanism may improve the likelihood of achieving a favorable response to therapeutic interventions targeted at the underlying pathophysiological cause.

Sharing is caring!

You cannot copy content of this page


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

Scroll to Top